id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-265799-qda5awuc	Carothers, Chancey	Acetylcysteine for the Treatment of Suspected Remdesivir‐Associated Acute Liver Failure in COVID‐19: A Case Series	2020-10-02		.txt	text/plain	3152	157	50	We report two cases of suspected remdesivirassociated acute liver failure (ALF) in patients with COVID-19 in which the liver failure improved with the addition of continuous infusion acetylcysteine and discontinuation of potentially hepatotoxic medications. 10 The EUA fact sheet provided by the manufacturer states that in the original compassionate use program of remdesivir in patients with severe or critical illness with COVID-19, liver function test abnormalities were reported in 12% of patients with a time to onset from first dose ranging from 1-16 days. One published case report by Leegwater discusses a case of acute liver failure 5 days after initiation of remdesivir in a patient with severe COVID-19 pneumonia. The use of the novel antiviral remdesivir in the treatment of COVID-19 pneumonia may put patients at risk of drug-associated acute liver failure.	./cache/cord-265799-qda5awuc.txt	./txt/cord-265799-qda5awuc.txt